Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

BACKGROUND: The FDA recently approved an anti-CTLA-4 antibody (Iplimumab) for the treatment of metastatic melanoma. This decision was based on Phase III results, which demonstrate that blocking this immune checkpoint provides a survival advantage in patients with advanced disease. As a single agent,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wada, Satoshi, Jackson, Christopher M, Yoshimura, Kiyoshi, Yen, Hung-Rong, Getnet, Derese, Harris, Timothy J, Goldberg, Monica V, Bruno, Tullia C, Grosso, Joseph F, Durham, Nicholas, Netto, George J, Pardoll, Drew M, Drake, Charles G
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3666941/
https://ncbi.nlm.nih.gov/pubmed/23557194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-89
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados